Galectin Therapeutics's total assets for Q3 2025 were $12.87M, a decrease of -17.54% from the previous quarter. GALT total liabilities were $138.17M for the fiscal quarter, a 4.07% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.